Q3 Earnings Forecast for 908 Devices Issued By William Blair

908 Devices Inc. (NASDAQ:MASS) – Equities researchers at William Blair increased their Q3 2025 EPS estimates for 908 Devices in a report issued on Monday, May 19th. William Blair analyst M. Larew now expects that the company will post earnings of ($0.07) per share for the quarter, up from their prior estimate of ($0.09). The consensus estimate for 908 Devices’ current full-year earnings is ($1.99) per share. William Blair also issued estimates for 908 Devices’ Q4 2025 earnings at ($0.02) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.05) EPS, Q3 2026 earnings at $0.00 EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at ($0.09) EPS.

908 Devices (NASDAQ:MASS) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. The business had revenue of $11.78 million for the quarter, compared to analyst estimates of $11.90 million. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 908 Devices in a report on Saturday, May 10th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, 908 Devices currently has an average rating of “Moderate Buy” and an average price target of $5.33.

908 Devices Trading Up 3.6%

NASDAQ:MASS opened at $4.94 on Wednesday. The company has a market cap of $177.15 million, a PE ratio of -2.79 and a beta of 0.26. The company has a 50 day simple moving average of $4.62 and a two-hundred day simple moving average of $3.29. 908 Devices has a 12 month low of $1.81 and a 12 month high of $6.86.

Insiders Place Their Bets

In other 908 Devices news, Director Mark Spoto acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was bought at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the purchase, the director now directly owns 62,971 shares in the company, valued at $270,145.59. The trade was a 18.88% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.70% of the stock is owned by insiders.

Institutional Trading of 908 Devices

A number of institutional investors have recently modified their holdings of the company. Geode Capital Management LLC grew its stake in 908 Devices by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 581,300 shares of the company’s stock valued at $1,279,000 after purchasing an additional 13,512 shares during the last quarter. Barclays PLC grew its stake in 908 Devices by 452.7% in the 3rd quarter. Barclays PLC now owns 46,214 shares of the company’s stock valued at $160,000 after acquiring an additional 37,853 shares during the period. Hsbc Holdings PLC grew its position in shares of 908 Devices by 32.2% in the fourth quarter. Hsbc Holdings PLC now owns 21,007 shares of the company’s stock valued at $46,000 after purchasing an additional 5,112 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in 908 Devices in the 4th quarter worth about $52,000. Finally, Prudential Financial Inc. purchased a new stake in shares of 908 Devices during the fourth quarter worth approximately $34,000. 88.06% of the stock is currently owned by institutional investors.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.